Michael L. Nickerson
Staff Scientist
Division of Cancer Epidemiology & Genetics, Laboratory of Tr
National Cancer Institute
United States of America
Biography
Dr. Nickerson obtained a bachelor’s degree in biology with honors from the St. Mary’s College of Maryland in 1985; a master’s degree in biochemistry from the State University of New York at Stony Brook in 1987; and a Ph.D. in molecular medicine from the George Washington University, Washington, D.C. in 2010. He has studied families with inherited clear cell, papillary, and chromophobe kidney cancer with Berton Zbar, M.D., at the National Cancer Institute (NCI) in Frederick, in collaboration with Marston Linehan, M.D., NCI in Bethesda. He left the NIH to serve as Director of the Genome Research Division at Transgenomic, Inc., where he conducted genetic analyses of KRAS and EGFR in tumors from lung cancer patients participating in clinical trials examining targeted therapy treatment. He joined DCEG in 2015. Dr. Nickerson has received awards from the Center of Excellence in Cancer Biology and Genomics, two NCI Major Opportunities for Clinical Cancer Research, and an NCI Director’s Intramural Innovation Award in 2013.
Research Interest
Urologic Cancer Genetics; Genetics of Bladder Cancer; Genetics of Prostate Cancer; Genetics of Kidney Cancer
Publications
-
Figueroa JD, Koutros S, Colt JS, Kogevinas M, Garcia-Closas M, Real FX, Friesen MC, Baris D, Stewart P, Schwenn M, Johnson A. Modification of occupational exposures on bladder cancer risk by common genetic polymorphisms. JNCI: Journal of the National Cancer Institute. 2015 Nov 1;107(11).
-
Ashktorab H, Mokarram P, Azimi H, Olumi H, Varma S, Nickerson ML, Brim H. Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer. Oncotarget. 2017 Jan 31;8(5):7852.
-
Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, Lou H, Brodie SA, Billaud JN, Zhang T, Bouk AJ. TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene. 2017 Apr;36(15):2172.
